Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland

NCT ID: NCT00473993

Last Updated: 2009-02-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Study Classification

OBSERVATIONAL

Study Start Date

2007-07-31

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatitis C viral infection is common among opioid addicts in Zurich, Switzerland. The majority undergoes a maintenance treatment with methadone, heroin or buprenorphine. While stabilized by an opioid maintenance treatment (OMT)chronic hepatitis C can be treated with pegylated interferon plus ribavirin. As not sufficiently known, the results are comparable to the results of the treatment of nonaddicts.

Our crossectional study investigates how many patients undergoing OMT are adequately investigated concerning hepatitis C. If not, why are they not adequately investigated and treated? Representative data are collected in the local clinics and medical practices involved in OMT in the Kanton of Zurich. The patients files are revised and the involved doctors are asked through a structured interview.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

www.seidenberg.ch/hepcop.pdf

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C, Chronic Substance Abuse Treatment Centers Opioid-Related Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Medical practices and clinics involved in opioid maintenance treatment in the Kanton of Zurich, Switzerland
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Zurich

OTHER

Sponsor Role collaborator

Seidenberg, Arztpraxis A., M.D.

INDIV

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

André Seidenberg, Dr.med.

Role: STUDY_DIRECTOR

research fellow EHAM, University of Zurich

Related Links

Access external resources that provide additional context or updates about the study.

http://www.seidenberg.ch/media/hepcop.pdf

download of the protocol of the HepCOP-study

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HepCOP Zurich

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Hepatitis C Treatment in Idaho County Jails
NCT06533319 NOT_YET_RECRUITING NA